William N. Newman, M.D.

Return To Care Team



OFFICES


FELLOWSHIP & POSTGRADUATE TRAINING

  • Fellowship, Cardiovascular Disease, Duke University, Durham, NC

INTERNSHIP/RESIDENCY

  • Residency: Internal Medicine, Duke University, Durham, NC

EDUCATION

  • Medical Degree: Duke University, Durham, NC
  • Undergraduate Degree: Princeton University, Princeton, NJ

CERTIFICATIONS

  • Internal Medicine; certificate valid indefinitely

SPECIALTIES

  • Interventional Cardiology

  • PUBLICATIONS/PRESENTATIONS/RESEARCH

RESEARCH & PUBLICATIONS

  • Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. Journal of American Medical Association. 2008;299(16):1903-1913
  • Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. American Heart Association Circulation. 2009 Feb 10;119(5):680-6
  • Lansky AJ, Ng VG, Mutlu H, Cristea E, Guiran JB, Midei M, Newman W, Sanz M, Sood P, Doostzadeh J, Su X, White R, Cao S, Sudhir K, Stone GW. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial. Catheter Cardiovasc Interv. 2009 Nov 1;74(5):719-27
  • Stone GW, Rizvi A, Sudhir K, Newman W, Applegate RJ, Cannon LA, Maddux JT, Cutlip DE, Simonton CA, Sood P, Kereiakes DJ; SPIRIT IV Investigators. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol. 2011 Jun 28;58(1):19-25.
  • Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ; SPIRIT IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N England J Med. 2010 May 6;362(18):1663-74.
  • Ito H, Hermiller JB, Yaqub M, Newman W, Sood P, Wang JC, Cannon L, Maddux JE, Sudhir K, Stone GW. Performance of everolimus-eluting versus paclitaxel-eluting coronary stents in small vessels: results from the SPIRIT III and SPIRIT IV clinical trials. J Interv Cardiol. 2011 Dec;24(6):505-13.
  • Gada H, Kirtane AJ, Newman W, Sanz M, Hermiller JB, Mahaffey KW, Cutlip DE, Sudhir K, Hou L, Koo K, Stone GW. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS Paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). JACC Cardiovasc Interv. 2013 Dec;6(12):1263-6.
  • Brener SJ, Kereiakes DJ, Simonton CA, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Smith RS Jr, Ying SW, Cutlip DE, Stone GW. Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial. Am Heart J. 2013 Dec;166(6):1035-42.
  • Mann T, Cowper PA, Peterson ED, Cubeddu G, Bowen J, Giron L, Cantor WJ, Newman WN, Schneider JE, Jobe RL, Zellinger MJ, Rose GC. Transradial coronary stenting: comparison with femoral access closed with an arterial suture device. Catheter Cardiovascular Interv. 2000 Feb;49(2):150-6.
  • Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS Jr, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2013 Sep;6(9):914-22.
  • Mann JT 3rd, Cubeddu G, Schneider JE, Newman WN, Rose GC, Zellinger MJ, Arrowood M, Bowen. Clinical Evaluation of Current Stent Deployment Strategies. J Invasive Cardiol. 1996;8
  • Mann T, Cubeddu G, Bowen J, Schneider JE, Arrowood M, Newman WN, Zellinger MJ, Rose GC. Stenting in acute coronary syndromes: a comparison of radial versus femoral access sites. J Am Coll Cardiol. 1998 Sep;32(3):572-6.
  • Mann T, Cubeddu RJ, Raynor L, Bowen J, Schneider JE, Rose G, Cubeddu G, Raza JA, Jobe RL, Newman W, Zellinger M. Coronary stenting in stable patients: identification of a low-risk subgroup that may not require adjunctive antiplatelet therapy. Catheter Cardiovascular Interv. 2003 Apr;58(4):459-66.

 



go to top